Biodexa Pharmaceuticals Enters into Non-binding Letter of Intent for Proposed Acquisition of Varian Biopharmaceuticals
18 mai 2023 08h30 HE
|
Biodexa Pharmaceuticals PLC
18 May 2023 Biodexa Pharmaceuticals Enters into Non-binding Letter of Intent for Proposed Acquisition of Varian Biopharmaceuticals Biodexa Pharmaceuticals PLC (NASDAQ: BDRX) (“Biodexa” or the...
2023 Bispecific CD3 Molecules in Oncology Analytical Tool: Covering 67 Companies Plus Partners who are Today Developing 148 Bispecific CD3 Drugs
16 mai 2023 12h18 HE
|
Research and Markets
Dublin, May 16, 2023 (GLOBE NEWSWIRE) -- The "Bispecific CD3 Molecules in Oncology: Analytical Tool" report has been added to ResearchAndMarkets.com's offering.There is a considerable and robust...
Ocean Biomedical (NASDAQ: OCEA) Announces 70% Increase in Price Target by EF Hutton from $10 to $17 on New Glioblastoma Results Validating Profound Tumor Suppression with Anti-Chi3L1 Antibody
01 mai 2023 08h01 HE
|
Ocean Biomedical, Inc.
Providence, RI, May 01, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the development and commercialization of scientifically compelling...
Oncology Based In-vivo CRO Market Size, Share & Trends Analysis Report 2023: A $2.3 Billion Market by 2030 - High Demand for Advanced Medicines and Implementation of International Standards by CROs
24 févr. 2023 06h43 HE
|
Research and Markets
Dublin, Feb. 24, 2023 (GLOBE NEWSWIRE) -- The "Oncology Based In-vivo CRO Market Size, Share & Trends Analysis Report By Indication (Blood Cancer, Solid Tumor), By Region, And Segment Forecasts,...
Enlivex Announces Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra in Patients with Advanced Solid Tumors
25 janv. 2023 08h37 HE
|
Enlivex Therapeutics Ltd
Nes-Ziona, Israel, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that...
Gastrointestinal stromal tumor Market Size 2023 Market Share, Top Companies report covers (Novartis,Bayer Aktiengesellschaft,Sun Pharmaceutical,Pfizer,NATCO Pharma), and Regional Analysis by Key Players,Segmentation and Forecast
24 janv. 2023 07h03 HE
|
Proficient Market Insights
PUNE, Jan. 24, 2023 (GLOBE NEWSWIRE) -- "Gastrointestinal stromal tumor Market" research report focus on overall information that can help to take decisions on current market situation....
Calidi Biotherapeutics and First Light Acquisition Group (FLAG) Announce Merger Agreement to Create a Publicly Listed, Clinical-Stage Biotechnology Company Utilizing Stem Cell-Based Platforms to Revolutionize Oncolytic Virotherapies
09 janv. 2023 10h33 HE
|
First Light Acquisition Group; Calidi Biotherapeutics, Inc.
-Total gross proceeds from transaction, before payment of transaction expenses, expected to be up to $82 million assuming no redemptions, combining a possible PIPE financing of up to $40 million and...
Enlivex Receives Allocetra IND Clearance From The U.S. Food And Drug Administration For Treatment Of Patients with Advanced Solid Malignancies
28 nov. 2022 08h00 HE
|
Enlivex Therapeutics Ltd
IND filing followed encouraging preclinical studies conducted in collaboration with Yale Cancer Center that showed a substantial, statistically significant survival benefit when Allocetra™ was...
Derm-Biome Pharmaceuticals, Inc. reports positive preclinical data in melanoma and squamous cell carcinoma, initiates a program aimed at advancing topical therapies for skin cancer to the clinic
12 oct. 2022 10h00 HE
|
Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a Vancouver based preclinical biopharmaceutical company focused on skin health and healthy aging, has...
Enlivex Announces New Preclinical Data in Murine Mesothelioma Model Showing a Substantial Survival Benefit with Allocetra as Monotherapy and in Combination with Cisplatin at the ESMO Congress 2022
12 sept. 2022 08h00 HE
|
Enlivex Therapeutics Ltd
Currently used cisplatin-based combination treatments have limited efficacy against mesothelioma, which is one of the deadliest solid cancers Combining cisplatin with Allocetra™ led to a...